Skip to content

Randomised controlled trial of treating dysfunctional breathing to reduce breathlessness in severe asthma

Randomised controlled trial of treating dysfunctional breathing to reduce breathlessness in severe asthma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN92818360
Enrollment
31
Registered
2006-09-29
Start date
2004-04-06
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory: Asthma Respiratory Asthma

Interventions

1. Patients will undergo breathing retraining with senior physiotherapist 2. Control

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 31 patients suffering from severe asthma: 1. Patients with diagnosis of asthma requiring regular maintenance medication (that includes high dose inhaled corticosteroid and long-acting ?2 agonist) 2. High medical resource usage 3. Non-smoker for at least one year 4. Historical evidence of reversibility

Exclusion criteria

Exclusion criteria: 1. Previous treatment for hyperventilation, dysfunctional breathing, or other functional disorder of respiratory mechanics 2. Participation in another trial involving respiratory intervention 3. Current or recent lower respiratory tract infection 4. Presence of other respiratory diseases 5. DLCO <70% predicted, significant co-morbid illness 6. Pregnancy or nursing mother 7. Psychiatric disorder 8. Hospitalisation for asthma within the prior 6 weeks

Design outcomes

Primary

MeasureTime frame
Change in University of California San Diego Shortness-of-Breath Questionnaire (SOBQ) score after treatment for dysfunctional breathing

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026